Aether Industries shares rally on listing, stock zooms 10% from IPO price on Dalal Street debut
时间:2024-06-26 10:08:56 阅读(143)
Aether Industries shares listed on the BSE and NSE (National Stock Exchange) today at a premium, amid the bullish sentiment on Dalal Street. Shares of the specialty chemicals manufacturer began trading on BSE at Rs 706.15 per share up 9.99% from the upper end of IPO price band of Rs 610-642 per share. On NSE the shares were trading at Rs 704 apiece Aether Industries IPO was fully subscribed by investors earlier last month with qualified institutional buyers (QIB) leading the bidding. On listing, Aether Industries had a market capitalization of Rs 8,790 crore.
The specialty chemical make came with its Rs 808 crore IPO last month. Of this Rs 627 crore was a fresh issue of equity shares while the remaining Rs 181 crore was an offer for sale (OFS) by existing shareholders of the company. Post issue, the promoter & promoter group shareholding will drop to 87.1% from 97%. Public shareholding in the company will increase to 12.9% from 3% earlier.
“Incorporated just 7 odd years back Aether Industries has become one of the fastest growing specialty chemical companies in India by growing its revenues at a CAGR of 49.5% between FY19 to FY21,” said analysts at Anand Rathi in their IPO note. “At the upper end of the IPO price band as of Aether Industries is valued at 72.3 times on annualized basis of FY22 earnings which looks fairly valued considering the growth opportunities for speciality chemicals in pharma, agrochemicals & FMCG space, and improving prospects for contractual manufacturing & CRAMS under Make-in-India initiatives,” they added. Anand Rathi had a ‘Subscribe for long-term’ rating on the issue.
On the other hand, Marwadi Financial Services took a more cautious approach, advising investors to subscribe with caution. “Considering the TTM (Dec-21) EPS of Rs 8.50 on a post issue basis, the company is going to list at a P/E of 75.6x with a market cap of Rs 79,918 million whereas its peers namely Clean Science & Technology Ltd and Fine Organic Ltd. are trading at PE of 82.7x and 80.2x,” they said. They added that the company has low and declining Operating Cash Flow to EBITDA ratio which is a reason to be cautious.
猜你喜欢
- s, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.
- Gold prices falling on US GDP, ECB, not US Fed; gold to remain rangebound between Rs 59500-58500 levels
- Tata Steel shares jump, then fall 1
- Stocks to watch- TCS, Larsen & Toubro, Maruti Suzuki India, Glenmark Life Sciences
- Goldman Sachs predicts 12% upside for Nifty; Overweight on resilient fundamentals
- Buy Coal India, SBI Cards stocks, charts show strength; fresh uptrend in Nifty possible above 16600
- Goldman Sachs initiates Affle share price coverage, projects 10% upside on strong digital advertising growth
- Bharat Drone Mahotsav 2022- Check out photos from India’s biggest Drone Festival
- Stocks To Watch- Zee, Adani Ports, ICICI General Insurance, Vedanta, PC Jeweller, SBI, JSW Steel, Inox Wind